⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68269 | 0.93 | — | — | |
| SCHEMBL8109972 | 0.85 | — | — | |
| SCHEMBL12060989 | 0.80 | — | — | |
| SCHEMBL896226 | 0.80 | — | — | |
| SCHEMBL7964693 | 0.78 | — | — | |
| SCHEMBL6567921 | 0.78 | TDP1 (0.43) | — | |
| SCHEMBL12060992 | 0.78 | — | — | |
| SCHEMBL22470615 | 0.77 | — | — | |
| SCHEMBL9781386 | 0.74 | — | — | |
| SCHEMBL863535 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115215848-A | Protein kinase inhibitor and derivative, preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2022-10-21 | — | — | CN | claimed |
| EP-3965884-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | claimed |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | claimed |
| WO-2020227549-A1 | MODULATORS OF THR-β AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | WO | claimed |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | US | claimed |
| US-10752609-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-25 | — | — | US | claimed |
| US-20200048240-A1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-13 | — | — | US | claimed |
| US-10450318-B2 | CXCR4 receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-22 | — | — | US | claimed |
| US-20190315714-A1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | claimed |
| EP-3544613-A1 | GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-10-02 | — | — | EP | claimed |
| WO-2008112473-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | claimed |
| WO-2007143521-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-13 | — | — | WO | claimed |
| US-20070287694-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | claimed |
| WO-2007092888-A2 | HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | claimed |
| US-20070185083-A1 | HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | claimed |
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | claimed |
| EP-1603858-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NeuroSearch A/S (DK) | 2005-12-14 | — | — | EP | claimed |
| WO-2004080377-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NEUROSEARCH A/S (DK) | 2004-09-23 | — | — | WO | claimed |
| EP-0355544-A2 | Substituted decalin amines, method for their preparation and their use in pesticides | BAYER AG (DE) | 1990-02-28 | — | — | EP | claimed |
| EP-0355540-A2 | Substituted cyclohexyl amines, process for their preparation and their use as pesticides | BAYER AG (DE) | 1990-02-28 | — | — | EP | claimed |